Literature DB >> 9485555

Does carbamazepine have a narrow therapeutic plasma concentration range?

M Bialer1, R H Levy, E Perucca.   

Abstract

Recently, there has been considerable discussion regarding the classification of drugs as a function of their therapeutic index, defined as the ratio between the upper and lower limits of the therapeutic range. Pharmacologic agents with a therapeutic index < 2 are classified as "narrow therapeutic index" (NTI) drugs. One of the agents classified as an NTI drug is carbamazepine. These recent developments led us to evaluate critically the evidence supporting the classification of carbamazepine as an NTI drug to address an old question: "Does carbamazepine have a narrow therapeutic plasma concentration range?"

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9485555     DOI： 10.1097/00007691-199802000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  12 in total

1.  Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.

Authors:  Xinyuan Zhang; Robert A Lionberger; Barbara M Davit; Lawrence X Yu
Journal:  AAPS J       Date:  2011-01-05       Impact factor: 4.009

2.  Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats.

Authors:  Tianjing Ren; Min Xiao; Mengbi Yang; Jiajia Zhao; Yufeng Zhang; Mengyun Hu; Yan Cheng; Hong Xu; Chunbo Zhang; Xiaoyu Yan; Zhong Zuo
Journal:  AAPS J       Date:  2019-07-18       Impact factor: 4.009

3.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.

Authors:  Laszlo Tothfalusi; Szilvia Speidl; Laszlo Endrenyi
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

4.  Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Authors:  Vangelis Karalis; Panos Macheras; Meir Bialer
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

5.  Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific.

Authors:  Baoman Li; Li Gu; Hongyan Zhang; Jingyang Huang; Ye Chen; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2007-06-27       Impact factor: 4.530

6.  Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Nelly E Villacreses; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

7.  Chronic carbamazepine administration attenuates dopamine D2-like receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Lisa Chang; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2008-02-27       Impact factor: 3.996

Review 8.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

9.  The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis.

Authors:  Zhaoxia Li; Zhuanglei Gao; Chengjuan Jin; Qinghui Guo; Lihua Wang; Shandan Wang; Xue Zhang; Yayun Wang
Journal:  Iran J Public Health       Date:  2014-12       Impact factor: 1.429

Review 10.  Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review.

Authors:  Sophia Yui Kau Fong; Qiong Gao; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.